Detail akcie Impact Bio Rg online

Business Summary: Impact Biomedical, Inc. is a biotechnology company engaged in discovering, developing, and patenting healthcare solutions. It discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. It has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. It also evaluates additional technologies.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Impact Biomedical Inc revenues increased from $0K to $25K. Net loss totaled $17.1M vs. income of $2.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net loss reflects Change in fair value of embedded derivat decrease from $5.7M (income) to $13.2M (expense), Professional Fees increase of 53% to $868K (expense).